Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting, 31332-31333 [E7-10850]
Download as PDF
jlentini on PROD1PC65 with NOTICES
31332
Federal Register / Vol. 72, No. 108 / Wednesday, June 6, 2007 / Notices
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human drug product will
include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA recently approved for marketing
the human drug product RAPLON
(Rapacuronium Bromide). RAPLON is
indicated as an adjunct to general
anesthesia to facilitate tracheal
intubation, and to provide skeletal
muscle relaxation during surgical
procedures. Subsequent to this
approval, the Patent and Trademark
Office received a patent term restoration
application for RAPLON (U.S. Patent
No. 5,418,226) from Akzo Nobel N.V.,
and the Patent and Trademark Office
requested FDA’s assistance in
determining this patent’s eligibility for
patent term restoration. In a letter dated
April 26, 2000, FDA advised the Patent
and Trademark Office that this human
drug product had undergone a
regulatory review period and that the
approval of RAPLON represented the
first permitted commercial marketing or
use of the product. Shortly thereafter,
the Patent and Trademark Office
requested that FDA determine the
product’s regulatory review period.
FDA has determined that the
applicable regulatory review period for
RAPLON is 1,724 days. Of this time,
1,304 days occurred during the testing
phase of the regulatory review period,
while 420 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: November 30,
1994. The applicant claims October 31,
1994, as the date the investigational new
drug application (IND) became effective.
VerDate Aug<31>2005
16:59 Jun 05, 2007
Jkt 211001
However, FDA records indicate that the
IND effective date was November 30,
1994, which was 30 days after FDA
receipt of the IND.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the act: June 25, 1998. FDA
has verified the applicant’s claim that
the new drug application (NDA) for
RAPLON (NDA 20–984) was initially
submitted on June 25, 1998.
3. The date the application was
approved: August 18, 1999. FDA has
verified the applicant’s claim that NDA
20–984 was approved on August 18,
1999.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 126 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments and ask for a
redetermination by August 6, 2007.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
December 3, 2007. To meet its burden,
the petition must contain sufficient facts
to merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document.Comments and petitions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: May 7, 2007.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. E7–10853 Filed 6–5–07; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0215]
Joint Meeting of the Endocrinologic
and Metabolic Drugs Advisory
Committee and the Drug Safety and
Risk Management Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees: Endocrinologic
and Metabolic Drugs Advisory
Committee and the Drug Safety and Risk
Management Advisory Committee.
General Function of the Committees:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on July 30, 2007, from 8 a.m. to 5
p.m.
Addresses: Electronic comments
should be submitted to https://
www.fda.gov/dockets/ecomments.
Select ‘‘2007N–0215—
Thiazolidinedione’’ and follow the
prompts to submit your statement.
Written comments should be submitted
to the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, by close of
business on July 23, 2007. All comments
will be posted without change,
including any personal information
provided. Comments received on or
before July 23, 2007, will be provided to
the committee before the meeting.
Location: Holiday Inn Gaithersburg,
Two Montgomery Village Ave.,
Gaithersburg, MD 20879. The hotel
telephone number is 301–948–8900.
Contact Person: Cathy A. Miller,
Center for Drug Evaluation and Research
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1099), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
Cathy.Miller1@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), codes
3014512536 and 3014512535. Please
call the Information Line for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
E:\FR\FM\06JNN1.SGM
06JNN1
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 72, No. 108 / Wednesday, June 6, 2007 / Notices
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
agency’s Web site and call the
appropriate advisory committee hot
line/phone line to learn about possible
modifications before coming to the
meeting.
Agenda: The Endocrinologic and
Metabolic Drugs and the Drug Safety
and Risk Management Advisory
Committees will meet in joint session to
discuss the cardiovascular ischemic/
thrombotic risks of the
thiazolidinediones, with focus on
rosiglitazone, as presented by FDA and
GlaxoSmithKline.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2007 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before July 6, 2007. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2:30 p.m. Those desiring to
make formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before June 28, 2007. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by June 29, 2007.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
VerDate Aug<31>2005
16:59 Jun 05, 2007
Jkt 211001
disabilities or special needs. If you
require special accommodations due to
a disability, please contact John
Lauttman, 301–827–7001, at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: May 31, 2007.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E7–10850 Filed 6–5–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources Special Emphasis Panel,
Comparative Medicine SEP.
Date: June 12, 2007.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Mohan Viswanathan, PhD,
Scientific Review Administrator, National
Center for Research Resources, or National
Institutes of Health, 6705 Democracy Blvd.,
1 Democracy Plaza, Rom 1084, MSC 4874,
Bethesda, MD 20892–4874, 301–435–0829,
viswanathanm@ncrr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine,
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure,
93.306, 93.333, National Institutes of Health,
HHS)
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
31333
Dated: May 30, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2794 Filed 6–5–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources Special Emphasis Panel,
T–SEP.
Date: June 26, 2007.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Room 1068, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: John R. Glowa, PhD,
Scientific Review Administrator, National
Center for Research Resources, or National
Institutes of Health, 6701 Democracy Blvd.,
1 Democracy Plaza, Room 1078, MSC 4874,
Bethesda, MD 20892–4874, 301–435–0807,
glowaj@mail.nih.gov.
Name of Committee: National Center for
Research Resources Special Emphasis Panel,
CR–SEP.
Date: July 10, 2007.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: John R. Glowa, PhD,
Scientific Review Administrator, National
Institutes of Health, NCRR/ or 6701
Democracy Boulevard, 1 Democracy Plaza,
Room 1078–MSC 4874, Bethesda, MD 20892–
4874, 301–435–0807, glowaj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389 Research Infrastructure,
E:\FR\FM\06JNN1.SGM
06JNN1
Agencies
[Federal Register Volume 72, Number 108 (Wednesday, June 6, 2007)]
[Notices]
[Pages 31332-31333]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-10850]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0215]
Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory
Committee and the Drug Safety and Risk Management Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committees: Endocrinologic and Metabolic Drugs Advisory
Committee and the Drug Safety and Risk Management Advisory Committee.
General Function of the Committees: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on July 30, 2007, from 8
a.m. to 5 p.m.
Addresses: Electronic comments should be submitted to https://
www.fda.gov/dockets/ecomments. Select ``2007N-0215--Thiazolidinedione''
and follow the prompts to submit your statement. Written comments
should be submitted to the Division of Dockets Management (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852, by close of business on July 23, 2007. All comments will be
posted without change, including any personal information provided.
Comments received on or before July 23, 2007, will be provided to the
committee before the meeting.
Location: Holiday Inn Gaithersburg, Two Montgomery Village Ave.,
Gaithersburg, MD 20879. The hotel telephone number is 301-948-8900.
Contact Person: Cathy A. Miller, Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm. 1099), Rockville, MD 20857,
301-827-7001, FAX: 301-827-6776, e-mail: Cathy.Miller1@fda.hhs.gov, or
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572
in the Washington, DC area), codes 3014512536 and 3014512535. Please
call the Information Line for up-to-date information on this meeting. A
notice in the Federal Register about last minute modifications that
impact a previously
[[Page 31333]]
announced advisory committee meeting cannot always be published quickly
enough to provide timely notice. Therefore, you should always check the
agency's Web site and call the appropriate advisory committee hot line/
phone line to learn about possible modifications before coming to the
meeting.
Agenda: The Endocrinologic and Metabolic Drugs and the Drug Safety
and Risk Management Advisory Committees will meet in joint session to
discuss the cardiovascular ischemic/thrombotic risks of the
thiazolidinediones, with focus on rosiglitazone, as presented by FDA
and GlaxoSmithKline.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on
the year 2007 and scroll down to the appropriate advisory committee
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before July
6, 2007. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2:30 p.m. Those desiring to make formal oral
presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before June 28, 2007. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by June 29,
2007.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact John Lauttman, 301-
827-7001, at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: May 31, 2007.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E7-10850 Filed 6-5-07; 8:45 am]
BILLING CODE 4160-01-S